31 related articles for article (PubMed ID: 9877238)
21. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
Haigentz M; Kim M; Sorich J; Lee J; Hochster H; Macapinlac M; Mirchandani D; Sewak S; Pavlick A; Volm M; Hamilton A; Muggia FM
Anticancer Drugs; 2003 Apr; 14(4):321-6. PubMed ID: 12679737
[TBL] [Abstract][Full Text] [Related]
23. Advances in supportive therapy.
Facchini T
Zentralbl Gynakol; 1996; 118(10):589-90. PubMed ID: 8912478
[No Abstract] [Full Text] [Related]
24. Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancer.
Safra T; Jeffers S; Sorich J; Muggia FM
Anticancer Drugs; 1998 Jul; 9(6):511-4. PubMed ID: 9877238
[TBL] [Abstract][Full Text] [Related]
25. Amifostine in reducing cisplatin toxicity.
Markman M
Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy for gynecologic tumors].
Machover D
Contracept Fertil Sex; 1996 Apr; 24(4):264-7. PubMed ID: 8704799
[No Abstract] [Full Text] [Related]
27. Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin.
Lin LL; Lakomy DS; Ning MS; Simpkins F; Jhingran A
Int J Gynecol Cancer; 2020 Apr; 30(4):409-423. PubMed ID: 32193219
[TBL] [Abstract][Full Text] [Related]
28.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
